Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.68 |
| ▸ | CCND1 | P24385 | 4/20 | 0.68 |
| ▸ | HTR2A | P28223 | 1/20 | 0.58 |
| ▸ | HTR2C | P28335 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 5/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29433250 | 1.00 | CDK4 (0.68) | CDK4CCND1HTR2AHTR2CKMT2A | |
| Dimethylamine SCHEMBL8570899 | 0.94 | CDK4 (0.61) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL3393616 | 0.83 | CDK4 (0.49) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL29372496 | 0.83 | CDK4 (0.76) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL3595410 | 0.83 | CDK4 (0.76) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL11366447 | 0.81 | CDK4 (1.00) | CDK4CCND1HTR2AHTR2CKMT2A | |
| Iodide SCHEMBL2581030 | 0.81 | CDK4 (0.73) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL25798842 | 0.81 | CDK4 (0.45) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL29374771 | 0.79 | CDK4 (0.78) | CDK4CCND1HTR2AHTR2CKMT2A | |
| SCHEMBL464099 | 0.79 | CDK4 (0.78) | CDK4CCND1HTR2AHTR2CKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-09-26 | — | — | US | claimed |
| CN-117903161-A | Tetrathiodiindole compound and derivative, synthetic method and application thereof | 衡阳师范学院 | 2024-04-19 | — | — | CN | claimed |
| CN-116969967-A | Synthesis method of polysubstituted-5, 10-dihydro [1,2,3,4] tetrathio [5,6-b:7,8-b' ] diindole and derivative | 衡阳师范学院 | 2023-10-31 | — | — | CN | claimed |
| CN-116813639-A | Synthesis method of polysubstituted [1,2,3,4,5] pentathio [6,7-b ] indole and derivative | 衡阳师范学院 | 2023-09-29 | — | — | CN | claimed |
| CN-112661750-B | Ketene-bridged quinazolinone thiazole compound and preparation method and application thereof | 西南大学 | 2022-10-21 | — | — | CN | claimed |
| CN-110092788-B | Substituted [1,2,4] triazolo [1,5-a ] pyrimidin-7-yl compounds as PDE2 inhibitors | 达特神经科学(开曼)有限公司 | 2022-02-25 | — | — | CN | claimed |
| CN-108658835-B | Method for synthesizing indole-2-ketone compound | 中国科学院成都有机化学有限公司 | 2021-12-03 | — | — | CN | claimed |
| EP-3597649-B1 | COMPOSITIONS CONTAINING SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE CAYMAN LTD (KY) | 2021-10-13 | — | — | EP | claimed |
| CN-112661750-A | Ketene-bridged quinazolinone thiazole compound and preparation method and application thereof | 西南大学 | 2021-04-16 | — | — | CN | claimed |
| CN-107619386-B | Aromatic ring [ c ] carbazole derivative and synthesis method thereof | 湘潭大学 | 2020-10-13 | — | — | CN | claimed |
| CN-107619386-A | A kind of aromatic ring simultaneously [c] carbazole analog derivative and its synthetic method | 湘潭大学 | 2018-01-23 | — | — | CN | claimed |
| CN-107235990-A | Polysubstituted indoles bithiophene and derivative and its synthetic method | 湘潭大学 | 2017-10-10 | — | — | CN | claimed |
| CN-106995400-A | A kind of compound and its salt and its synthetic method | 湘潭大学 | 2017-08-01 | — | — | CN | claimed |
| US-20170057967-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | DART NEUROSCIENCE LLC | 2017-03-02 | — | — | US | claimed |
| CN-106459062-A | Substituted [1,2,4] triazolo [1,5-a ] pyrimidin-7-yl compounds as PDE2 inhibitors | 达特神经科学(开曼)有限公司 | 2017-02-22 | — | — | CN | claimed |
| CN-106117113-A | Polysubstituted carbazole, derivant and synthetic method thereof | 湘潭大学 | 2016-11-16 | — | — | CN | claimed |
| CN-101326201-B | Catalyst components for the polymerization of olefins | BASELL POLIOLEFINE SRL | 2011-11-02 | — | — | CN | claimed |
| CN-1271051-C | Aza aromatic ring substitutional four branched functional molecule material and preparation method | UNIV FUDAN (CN) | 2006-08-23 | — | — | CN | claimed |
| CN-1539820-A | Aza aromatic ring substitutional four branched functional molecule material and preparation method | 复旦大学 | 2004-10-27 | — | — | CN | claimed |
| US-4076537-A | Light-sensitive materials containing organo tellurium or selenium compounds and sensitizers | FUJI PHOTO FILM CO., LTD. (JA) | 1978-02-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170057967-A1 | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS | PDE12, PDE2A, TDP2 | CDK4 1809/4885CCND1 1845/4885HTR2A 413/4885 |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | CDK4 4312/4885CCND1 3961/4885HTR2A 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.